Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

NCT00137917 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

478

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL: Meningococcal serogroup B vaccine

Sponsor

GlaxoSmithKline